Literature DB >> 19131591

Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer.

Marc McClelland1, Liujian Zhao, Shannon Carskadon, Douglas Arenberg.   

Abstract

Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine that is overexpressed in lung cancer. The MIF receptor was recently discovered and found to be the invariant chain of the HLA class II molecule, CD74. We hypothesized that the expression of this receptor-ligand pair in lung cancer is associated with the angiogenic activity and level of CXC chemokine expression in human specimens of non-small cell lung cancer. We, therefore, performed immunolocalization of CD74 and compared it with the localization of MIF in non-small cell lung cancer to determine their respective locations, as well as the relationship between the co-expression of MIF-CD74 and angiogenic CXC chemokines with tumor angiogenesis. We found intense CD74 expression by immunohistochemistry in 57 of 70 tumors with minimal to no staining in the remaining 13 tumors. Comparing the localization of CD74 with its putative ligand, MIF, we found that CD74 and MIF were co-expressed in tumors in close proximity, and that co-expression of the MIF-CD74 pair was associated with both higher levels of tumor-associated angiogenic CXC chemokines (ie, the ELR score) and greater vascularity compared with tumors in which MIF-CD74 co-expression was not present. We also found that MIF induced angiogenic CXC chemokine expression in an autocrine manner in vitro, a function that was specifically inhibited by antibodies to CD74.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131591      PMCID: PMC2630571          DOI: 10.2353/ajpath.2009.080463

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase.

Authors:  M Asif Amin; Olga V Volpert; James M Woods; Pawan Kumar; Lisa A Harlow; Alisa E Koch
Journal:  Circ Res       Date:  2003-07-24       Impact factor: 17.367

2.  Human major histocompatibility complex class II invariant chain is expressed on the cell surface.

Authors:  C J Wraight; P van Endert; P Möller; J Lipp; N R Ling; I C MacLennan; N Koch; G Moldenhauer
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

3.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response.

Authors:  Robert A Mitchell; Hong Liao; Jason Chesney; Gunter Fingerle-Rowson; John Baugh; John David; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

4.  Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy (CLSM).

Authors:  W Baschong; R Suetterlin; R H Laeng
Journal:  J Histochem Cytochem       Date:  2001-12       Impact factor: 2.479

5.  Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF).

Authors:  Hong Liao; Richard Bucala; Robert A Mitchell
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

6.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.

Authors:  H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

7.  Atypical adenomatous hyperplasia of lung: its incidence and analysis of clinical, glycohistochemical and structural features including newly defined growth regulators and vascularization.

Authors:  Klaus Kayser; Johnson Obiefune Nwoye; Zdravko Kosjerina; Thorsten Goldmann; Ekkehard Vollmer; Herbert Kaltner; Sabine André; Hans-Joachim Gabius
Journal:  Lung Cancer       Date:  2003-11       Impact factor: 5.705

8.  The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting.

Authors:  G Fingerle-Rowson; O Petrenko; C N Metz; T G Forsthuber; R Mitchell; R Huss; U Moll; W Müller; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

9.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.

Authors:  Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

10.  Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Authors:  Thorsten Hagemann; Stephen C Robinson; Richard G Thompson; Kellie Charles; Hagen Kulbe; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

View more
  28 in total

1.  MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.

Authors:  Priyadharsini Nagarajan; Kathleen L Tober; Judith A Riggenbach; Donna F Kusewitt; Amy M Lehman; Thais Sielecki; James Pruitt; Abhay R Satoskar; Tatiana M Oberyszyn
Journal:  Mol Cancer Res       Date:  2014-05-21       Impact factor: 5.852

2.  Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.

Authors:  Leona Mawhinney; Michelle E Armstrong; Ciaran O' Reilly; Richard Bucala; Lin Leng; Gunter Fingerle-Rowson; Darren Fayne; Michael P Keane; Aisling Tynan; Lewena Maher; Gordon Cooke; David Lloyd; Helen Conroy; Seamas C Donnelly
Journal:  Mol Med       Date:  2015-04-16       Impact factor: 6.354

3.  Lung cancer diagnosis from proteomic analysis of preinvasive lesions.

Authors:  S M Jamshedur Rahman; Adriana L Gonzalez; Ming Li; Erin H Seeley; Lisa J Zimmerman; Xueqiong J Zhang; M Lisa Manier; Sandra J Olson; Ronak N Shah; Alison N Miller; Joe B Putnam; York E Miller; Wilbur A Franklin; William J Blot; David P Carbone; Yu Shyr; Richard M Caprioli; Pierre P Massion
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

4.  CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Authors:  Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 5.  Stromal-dependent tumor promotion by MIF family members.

Authors:  Robert A Mitchell; Kavitha Yaddanapudi
Journal:  Cell Signal       Date:  2014-09-30       Impact factor: 4.315

6.  Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.

Authors:  Douglas Arenberg; Tracy R Luckhardt; Shannon Carskadon; Liujian Zhao; Mohammad A Amin; Alisa E Koch
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

Review 7.  Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer.

Authors:  Camila Cristina Guimarães Nobre; Josélio Maria Galvão de Araújo; Thales Allyrio Araújo de Medeiros Fernandes; Ricardo Ney Oliveira Cobucci; Daniel Carlos Ferreira Lanza; Vânia Sousa Andrade; José Veríssimo Fernandes
Journal:  Pathol Oncol Res       Date:  2016-10-23       Impact factor: 3.201

8.  Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis.

Authors:  Suhui Wu; Junfang Lian; Huijuan Tao; Haixia Shang; Li Zhang
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

9.  Identification of potential therapeutic targets in human head & neck squamous cell carcinoma.

Authors:  Jing Han; Mitomu Kioi; Wei-Sing Chu; Jan L Kasperbauer; Scott E Strome; Raj K Puri
Journal:  Head Neck Oncol       Date:  2009-07-14

10.  A role for NRAGE in NF-kappaB activation through the non-canonical BMP pathway.

Authors:  Nicholas Matluk; Jennifer A Rochira; Aldona Karaczyn; Tamara Adams; Joseph M Verdi
Journal:  BMC Biol       Date:  2010-01-25       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.